Teriparatide

from Wikipedia, the free encyclopedia
Teriparatide
Teriparatide
Identifier
External IDs
Drug information
ATC code H05 AA02
DrugBank DB06285

Teriparatide is a recombinant human parathyroid hormone fragment (PTH 1 - 34, consisting of the first 34 amino acids of the parathyroid hormone) for the treatment of osteoporosis . Its main use is the treatment of postmenopausal women with overt osteoporosis and a high risk of fractures. The active ingredient was approved in the USA under the brand name Forsteo for Lilly Pharma in November 2002 and in Germany at the end of 2003 as the trademark Forsteo . The active ingredient is produced using recombinant DNA technology .

In one study, teriparatide also caused an increase in bone density in patients with osteogenesis imperfecta ; the number of fractures was not significantly different in this small study.

Risks

In studies on rats, teriparatide shows an increased risk of osteosarcomas , which was not confirmed in studies on humans. This may be because rat bones continue to grow for a lifetime. The tumors were found on the ends of the bone that had grown after the injections. Even nine years after approval, only two cases of osteosarcoma were known with teriparatide. The FDA classified this risk as "extremely rare" (1 in 100,000 people) and is only slightly higher than the normal incidence for those over 60 years of age (0.4 in 100,000).

Contraindications

The medicine must not be used in patients who have other bone disorders such as Paget's disease , bone cancer or bone metastases , who have had radiation therapy to the skeleton, who have hypercalcaemia or an unexplained increase in the enzyme alkaline phosphatase , or who have severe kidney disease Suffer.

Web links

Individual evidence

  1. ↑ KG Saag, E Shane, S Boonen et al .: Teriparatide or alendronate in glucocorticoid-induced osteoporosis . In: The New England journal of medicine . 357, No. 20, November 2007, pp. 2028-39. doi : 10.1056 / NEJMoa071408 . PMID 18003959 .
  2. ↑ Orwoll ES: Evaluation of teriparatide treatment in adults with osteogenesis imperfecta in J Clin Invest. 2014 Feb 3; 124 (2): 491-8. doi: 10.1172 / JCI71101 .
  3. ↑ https://www.drugs.com/pro/forteo.html
  4. ↑ M. Kawai, UI Mödder, S. Khosla, CJ Rosen: Emerging therapeutic opportunities for skeletal restoration . In: Nature Reviews Drug Discovery . 10, No. 2, 2011, pp. 141–156. doi : 10.1038 / nrd3299 . PMID 21283108 . PMC 3135105 (free full text).
  5. ↑ R. Rizzoli, JY Reginster, S. Boonen, GR Breart, A. Diez-Perez, D. Felsenberg, JM Kaufman, JA Kanis, C. Cooper: Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis . In: Calcified Tissue International . 89, No. 2, 2011, pp. 91-104. doi : 10.1007 / s00223-011-9499-8 . PMID 21637997 . PMC 3135835 (free full text).